Blueprint Medicines names Kate Haviland as CEO; other moves

6 January 2022

US precision cancer therapy specialist Blueprint Medicines (Nasdaq: BPMC) has appointed Kate Haviland to succeed Jeff Albers as chief executive (CEO), effective April 4, 2022.

At that time, Mr Albers will transition from his current role as chairman, president and CEO to executive chairman of the board of directors and Ms Haviland will transition from her current role as chief operating officer (COO) to president and CEO. In addition, Ms Haviland will be appointed to serve on the company’s board of directors, effective April 4, 2022.

Blueprint Medicines also announced today that Christina Rossi has been promoted from chief commercial officer to COO. In her new role, Ms. Rossi will retain leadership of global commercial strategy and operations, and expand her oversight to include portfolio strategy and program management, corporate development, and corporate affairs, effective April 4, 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK